Angelini Pharma to Buy Catalyst in Deal Worth $4.1 Billion (1)

Italian drugmaker Angelini Pharma SpA agreed to buy Catalyst Pharmaceuticals Inc. for $4.1 billion as it looks to grow in the US and build a footprint in rare diseases.

Angelini Pharma will pay $31.50 per share in cash for Catalyst, a 21% premium to the US-listed company’s closing share price on April 22, it said in a statement Thursday. Bloomberg previously reported on the potential deal.

Read More: Italy’s Angelini Said to Explore Catalyst Pharma Acquisition

With Catalyst, family-owned Angelini will gain medicines for rare diseases such as Duchenne muscular dystrophy and Lambert-Eaton myasthenic syndrome that tend to command higher ...